fbpx

Patient Recruitment Insights

September 8th, 2023

Why HCP Outreach is so Important For Recruiting Patients in Rare Disease

When it comes to recruiting patients for clinical trials in rare diseases, HCP outreach and support is essential. Most trials in the rare disease space struggle with patient recruitment unless they have a well thought out strategy on how to include HCPs in the recruitment process. 

December 7th, 2022

Compensation norms create inequity in clinical trials.

Imagine a patient participating in a clinical trial for a new vaccine. They take a half day of PTO to visit the clinic, which is a short 15-minute drive from their home. After an hour visit, they are given $50 as compensation – a reasonable amount which they spend on a nice dinner. This describes

November 8th, 2022

Secondary conditions and race/ethnicity affect type 2 diabetes patients’ interest in clinical trial participation.

SubjectWell recently fielded a survey engaging over 300 type 2 diabetes patients. The findings showed that diabetes patients demonstrated high overall interest in clinical trial participation, but secondary conditions caused by their diabetes can shift that interest higher or lower. According to the CDC, more than 33 million Americans have type 2 diabetes. As patients’

September 8th, 2022

Across multiple demographics, accommodations boost patient interest in clinical trial participation and barriers lower interest.

Minority populations are significantly underrepresented in clinical research. When comparing the FDA’s recent Drug Trial Snapshots data with US Census data, women, white patients, and older patients are shown to be overrepresented in clinical trials. Black patients make up just 8% and Hispanic patients 11% of trial participants — much lower than their general population

June 17th, 2022

Spanish-speaking patients show strong interest in clinical trial participation in the US.

For a clinical trial to be successful, patients need to be the top priority. However, language barriers faced during the clinical trial process can often result in lower participation rates of non-English speakers, an unsatisfactory patient experience and, ultimately, imprecise data. In the US, the leading country in clinical trial participation each year, language barriers

May 28th, 2022

Patient attitudes toward clinical research continue to evolve during the COVID-19 pandemic.

At SubjectWell, we have been conducting an ongoing survey since the beginning of the pandemic to understand how patient attitudes toward clinical research participation have been affected. As the coronavirus pandemic continues, we continue to see how the rapidly evolving situation is also changing the clinical trial landscape. The third round of our survey was

March 31st, 2022

Non-small cell lung cancer patients show strong interest in clinical trial participation across disease progression.

In February 2022, SubjectWell announced the expansion of its proven marketplace to include oncology clinical trials, beginning with non-small cell lung cancer (NSCLC). Lung cancer is by far the leading cause of cancer death, and more specifically, the vast majority of lung cancer diagnoses are NSCLC. To develop a better understanding of NSCLC patients’ attitudes

March 14th, 2022

SubjectWell expands its proven marketplace to include non-small cell lung cancer trials

SubjectWell has been providing risk-free patient recruitment for 10 years, building awareness of the benefits of clinical research and offering choice to patients with chronic ambulatory health conditions by screening for multiple studies at once. And now we’re taking our marketplace one step further. In February 2022, SubjectWell expanded our proven clinical trial marketplace to

January 4th, 2022

Younger Parkinson’s patients show strong interest in clinical trial participation and high comfort with digital research technology.

Parkinson’s disease (PD), a lifelong and progressive neurological condition, affects about one million people in the United States alone. Primary PD symptoms involve motor impairments, like slowness of movement, gait problems, rigidity, and tremors, as well as significant “invisible” non-motor symptoms, cognitive problems, anxiety, depression, sleep disorders, and digestive problems, which can be disabling. Within

September 10th, 2021

Survey of asthma patients found subgroup with limited acceptance of diagnosis.

In the US today, approximately 20 million adults have asthma. With no cure for asthma, around 8% of Americans use medication to prevent asthma attacks and control symptoms, while pharmaceutical companies quest for new or improved treatments and drug combinations. To better understand patient attitudes toward their breathing problems or asthma diagnosis – along with

June 21st, 2021

International survey shows country with lowest healthcare usage and trust correlates to highest likelihood of clinical trial participation.

Quality care in any healthcare system relies heavily on patients developing and maintaining trust in their healthcare professionals (HCPs). As we’ve witnessed throughout the COVID-19 pandemic, local HCPs informing and guiding patients on proper treatment and preventive measures were more successful than similar messages pushed from government agencies or medical institutions. However, while patient trust

April 14th, 2021

The Rise of Decentralized Clinical Trials Is Disrupting Traditional Patient Recruitment

Buzz about decentralized clinical trials (DCTs) and hybrid designs has been around for years; however, it took the in-person restrictions brought about by COVID-19 to accelerate their adoption. The major advantages of DCTs – untethered recruiting from physical site locations, patient-centric accommodations, integration of modern technology – all drastically affect the role of sites in

April 5th, 2021

Surprisingly, patients are more willing to participate in a COVID-19 vaccine trial as coronavirus vaccines become more widely available.

Marking more than a year since the pandemic began, the world has witnessed how essential clinical research is to creating safe, life-changing treatments. And, more specifically, people are clearly seeing how clinical trials have led to bringing the current coronavirus vaccines to market, now with more than 118 million doses administered in the US alone.

January 5th, 2021

As liver disease cases rise in the US, data shows that patients both at-risk and with a diagnosis of liver disease are willing to participate in clinical research.

Known as the silent liver disease, nonalcoholic fatty liver disease (NAFLD) affects between 30% and 40% of all adults in the US. Fatty liver disease (FLD) can also lead to nonalcoholic steatohepatitis (NASH). Together, FLD and NASH impact the lives of more than 100 million Americans. And NASH is on the rise: by 2030, prevalent

November 13th, 2020

Concerns around clinical trial participation continue to differ by race.

Since the start of the pandemic, SubjectWell has kept a close eye on patient attitudes and feelings toward clinical trials. After all, right now is arguably the most critical time for clinical trial participation as COVID-19 cases continue to rise worldwide and vaccines and treatments are still being tested. By understanding what prevents or encourages